Cargando…

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis

Although currently available immune checkpoint inhibitors with similar but slightly different indications are recommended for patients with advanced non-small cell lung cancer (NSCLC), their effects by programmed death-ligand-1 (PD-L1) expression level are not yet known. This meta-analysis aims to a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jinchul, Cho, Jinhyun, Lee, Moon Hee, Lim, Joo Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078964/ https://www.ncbi.nlm.nih.gov/pubmed/30082893 http://dx.doi.org/10.1038/s41598-018-30277-0

Ejemplares similares

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis
por: Kim, Jinchul, et al.
Publicado: (2022)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
por: Ishii, Hidenobu, et al.
Publicado: (2020)

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
por: Jang, Jae Yeon, et al.
Publicado: (2023)

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
por: Negrao, Marcelo V., et al.
Publicado: (2022)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
por: Yang, Haitao, et al.
Publicado: (2017)

Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
por: Ancel, Julien, et al.
Publicado: (2019)

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors
por: Bains, Savreet, et al.
Publicado: (2022)

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
por: Pattanaik, Smita, et al.
Publicado: (2019)

The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC
por: Yuan, Pei, et al.
Publicado: (2020)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
por: Leapman, Michael S., et al.
Publicado: (2020)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
por: Rajakumar, Timothy, et al.
Publicado: (2022)

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2023)

Tumor glycolytic profiling through (18)F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
por: Silva, Saulo Brito, et al.
Publicado: (2022)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
por: Dall’Olio, Filippo G., et al.
Publicado: (2022)

Reduced FEV(1) as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
por: Shen, Yi-Luen, et al.
Publicado: (2022)

Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study
por: Zhang, Jian, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review
por: Wagner, Gernot, et al.
Publicado: (2020)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
por: De Marchi, Pedro, et al.
Publicado: (2023)

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country
por: How, Soon Hin, et al.
Publicado: (2022)

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
por: Liang, Yuehua, et al.
Publicado: (2022)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer
por: Noh, Myung-Giun, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rho4ha9dhuo3gf02o4t07vthdt